vTv Therapeutics reports FY2022 net loss of $19.2M; advances TTP399 toward Phase 3

vTv Therapeutics Inc.

Net loss attributable to shareholders was $19.2M ($0.26/share) for FY2022 vs $13.0M ($0.21/share) in FY2021.
Cash and cash equivalents at Dec 31, 2022: $12.1M, down from $13.4M a year earlier.
Received ~$12.0M from G42 Investments in Feb 2023 via early promissory note payment at 3.75% discount.
Appointed Steven Tuch as EVP/CFO (Dec 2022) and Elizabeth Keiley as EVP/General Counsel (Feb 2023).
Preparing to initiate first of two Phase 3 trials of TTP399 for Type 1 diabetes in H2 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

vTv Therapeutics Inc. reported the fourth quarter and year ended December 31, 2022 results: net income Net loss attributable to vTv shareholders for the three months ended December 31, 2022, was $4.7 million or $0.06 per ba, EPS $0.06 per basic share.

Period: the fourth quarter and year ended December 31, 2022
Net income: Net loss attributable to vTv shareholders for the three months ended December 31, 2022, was $4.7 million or $0.06 per ba
EPS: $0.06 per basic share
Result: reported results

Exact text from the filing

vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal year ended December 31, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

vTv Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001641489-23-000007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.